ClexBio

ClexBio is pioneering a novel approach to tissue engineering with its VivoSet™ platform, which creates perfusable, cell-synthesized tissues designed for rapid engraftment and long-term functionality. The company is advancing a preclinical pipeline of therapeutic tissues for liver failure, diabetes, and cardiac repair, aiming to address chronic diseases where traditional drugs and cell therapies fall short. As a private, preclinical company, ClexBio is seeking partnerships to accelerate development and leverage its scalable, automated manufacturing technology. Its core value proposition lies in creating biologically integrated tissues that enable stem cell therapies to achieve durable therapeutic effects.

VivoSet™ platform for scalable manufacturing of fully vascularized, cell-synthesized tissues using injection molding in parallel bioreactors.

Competes with other tissue engineering and regenerative medicine companies developing scaffold-based or 3D-bioprinted tissues, as well as cell therapy companies targeting the same indications. Differentiation lies in the integrated vascular network and scalable injection-molding manufacturing process.